Pediatrix Medical Group (MD) stock surged 8.43% in pre-market trading on Thursday, following the release of its better-than-expected fourth quarter 2024 results and an upbeat outlook for 2025.
For the fourth quarter, the company reported adjusted earnings per share of $0.51, beating the consensus estimate of $0.37. Revenue of $502.4 million also topped expectations of $486.2 million, driven by an 8.7% increase in same-unit revenue.
Looking ahead, Pediatrix anticipates its 2025 Adjusted EBITDA to range between $215 million and $235 million, reflecting continued growth and operational efficiency efforts. The company expects to benefit from its recent portfolio restructuring and overhead expense reductions.